

DEPARTMENT OF THE AIR FORCE 59TH MEDICAL WING (AETC) JOINT BASE SAN ANTONIO - LACKLAND TEXAS

5 JAN 2017

MEMORANDUM FOR 959 CSPS

ATTN: CAPT JOHN HUNNINGHAKE

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

- Your paper, entitled <u>First Transatlantic Transport on Extracorporeal Life Support for Hypercapneic Respiratory Failure</u> presented at/published to <u>2017 Critical Care Congress</u> (<u>Society of Critical Care Medicine Annual Meeting</u>), <u>Honolulu</u>, <u>HI</u>, <u>21-25 Jan 2017</u> in accordance with MDWI 41-108, has been approved and assigned local file #17013.
- 2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.
- 3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are 59 MDW staff member, we can forward your request for funds to the designated wing POC.
- 4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

LINDA STEEL-GOODWIN, Col, USAF, BSC Director, Clinical Investigations & Research Support

hinda Steel-Goodin

PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS

INSTRUCTIONS

USE ONLY THE MOST CURRENT 59 MDW FORM 3039 LOCATED ON AF E-PUBLISHING

- 1. The author must complete page two of this form:
 - a. In Section 2, add the funding source for your study [e.g., 59 MDW CRD Graduate Health Sciences Education (GHSE) (SG5 O&M); SG5 R&D; Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRDP); NIH; Congressionally Directed Medical Research Program (CDMRP); Grants; etc.1
 - b. In Section 2, there may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication. Please state "YES" or "NO" in Section 2 of the form, if you need publication funding support.
- 2. Print your name, rank/grade, sign and date the form in the author's signature block or use an electronic signature.
- 3. Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protocol Title" box.
- 4. Attach a copy of your abstract, paper, poster and other supporting documentation.
- 5. Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for review/approval.
- 6. On page 2, have either your unit commander, program director or immediate supervisor:
 - a. Print their name, rank/grade, title; sign and date the form in the approving authority's signature block or use an electronic signature.
- 7. Submit your completed form and all supporting documentation to the CRD for processing (59crdpubspres@us.af.mil). This should be accomplished no later than 30 days before final clearance is required to publish/present your materials. If you have any questions or concerns, please contact the 59 CRD/Publications and Presentations Section at 292-7141 for assistance.
- 8. The 59 CRD/Publications and Presentations Section will route the request form to clinical investigations, 502 ISG/JAC (Ethics Review) and Public Affairs (59 MDW/PA) for review and then forward you a final letter of approval or disapproval.
- 9. Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. Note: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.
- 10. If your manuscript is accepted for scientific publication, please contact the 59 CRD/Publications and Presentations Section at 292-7141. This information is reported to the 59 MDW/CC. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DITC). See 59 MDWI 41-108, Presentation and Publication of Medical and Technical Papers, for additional information.
- 11. The Joint Ethics Regulation (JER) DoD 5500.07-R, Standards of Conduct, provides standards of ethical conduct for all DoD personnel and their interactions with other non-DoD entities, organizations, societies, conferences, etc. Part of the Form 3039 review and approval process includes a legal ethics review to address any potential conflicts related to DoD personnel participating in non-DoD sponsored conferences, professional meetings, publication/presentation disclosures to domestic and foreign audiences, DoD personnel accepting non-DoD contributions, awards, honoraria, gifts, etc. The specific circumstances for your presentation will determine whether a legal review is necessary. If you (as the author) or your supervisor check "NO" in block 17 of the Form 3039, your research or technical documents will not be forwarded to the 502 ISG/JAC legal office for an ethics review. To assist you in making this decision about whether to request a legal review, the following examples are provided as a guideline:

For presentations before professional societies and like organizations, the 59 MDW Public Affairs Office (PAO) will provide the needed review to ensure proper disclaimers are included and the subject matter of the presentation does not create any cause for DoD concern.

If the sponsor of a conference or meeting is a DoD entity, an ethics review of your presentation is not required, since the DoD entity is responsible to obtain all approvals for the event.

If the sponsor of a conference or meeting is a non-DoD commercial entity or an entity seeking to do business with the government, then your presentation should have an ethics review.

If your travel is being paid for (in whole or in part) by a non-Federal entity (someone other than the government), a legal ethics review is needed. These requests for legal review should come through the 59 MDW Gifts and Grants Office to 502 ISG/JAC.

If you are receiving an honorarium or payment for speaking, a legal ethics review is required.

If you (as the author) or your supervisor check "YES" in block 17 of the Form 3039, your research or technical documents will be forwarded simultaneously to the 502 ISG/JAC legal office and PAO for review to help reduce turn-around time. If you have any questions regarding legal reviews, please contact the legal office at (210) 671-5795/3365, DSN 473.

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement:

'The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans:

"The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DODI 3216.02_AFI 40-402."

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN

"The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."

PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS								
1. TO: CLINICAL RESEARCH 2. FROM: (Author	The state of the s		3. GME/GHSE STU	JDENT: 4.	PROTOCOL NUMBER:			
land and a second	ake, O-3, MC, 959 CS		⊠ YES □ I	N/	'A			
5. PROTOCOL TITLE: (NOTE: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039								
must be submitted for review and approval.)								
Case Report								
6. TITLE OF MATERIAL TO BE PUBLISHED OR PRESENTED:								
First Transatlantic Transport on Extracorporeal Life Support for Hypercapneic Respiratory Failure								
7. FUNDING RECEIVED FOR THIS STUDY? YES NO FUNDING SOURCE:								
8. DO YOU NEED FUNDING SUPPORT FOR PUBLICATION PURPOSES: YES NO								
9. IS THIS MATERIAL CLASSIFIED? YES NO								
10. IS THIS MATERIAL SUBJECT TO ANY LEGAL RESTRICTIONS FOR PUBLICATION OR PRESENTATION THROUGH A COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA), MATERIAL TRANSFER AGREEMENT (MTA), INTELLECTUAL PROPERTY RIGHTS AGREEMENT ETC.? YES NO NOTE: If the answer is YES then attach a copy of the Agreement to the Publications/Presentations Request Form.								
11. MATERIAL IS FOR: 🛛 DOMESTIC RELEASE 🗌 FOREIGN RELEASE								
CHECK APPROPRIATE BOX OR BOXES FOR APPROVAL WITH THIS REQUEST. ATTACH COPY OF MATERIAL TO BE PUBLISHED/PRESENTED. 11a. PUBLICATION/JOURNAL (List intended publication/journal.)								
14b DUDURNED ARCTRACT // ist intended journal \								
11b. PUBLISHED ABSTRACT (List intended journal.)								
11c. POSTER (To be demonstrated at meeting: name of meeting, city, state, and date of meeting.)								
11e. OTHER (Describe: name of meeting, city, state, and date of meeting.)								
ATTACLIST DESCRIPTION OF ATTACLIST DESCRIPTION OF D								
12. HAVE YOUR ATTACHED RESEARCH/TECHNICAL MATERIALS BEEN PREVIOUSLY APPROVED TO BE PUBLISHED/PRESENTED? ☐ YES ☑ NO ASSIGNED FILE # DATE								
13. EXPECTED DATE WHEN YOU WILL NEED THE CRD TO SUBMIT YOUR CLEARED PRESENTATION/PUBLICATION TO DTIC NOTE: All publications/presentations are required to be placed in the Defense Technical Information Center (DTIC).								
DATE								
January 09, 2017								
14. 59 MDW PRIMARY POINT OF CONTACT (Last Name, First Name, M.I., email)				15. DUTY PHONE/PAGER NUMBER				
Hunninghake, John, C, john.c.hunninghake.mil@mail.mil					210-513-7605			
16. AUTHORSHIP AND CO-AUTHOR(S) List in		ar in the manuscript.						
LAST NAME, FIRST NAME AND M.I.	GRADE/RANK	SQUADRON/GROUP	OFFICE SYMBOL	INSTI	TUTION (If not 59 MDW)			
Primary/Corresponding Author Hunninghake, John C	0-3	959 CSPS						
	0-4	59 MDSP/SGMSP						
b. Skabelund, Andrew J	CIVILIAN			CIVILIAN				
c. Hagedorn, Scott	CIVILIAN	CIVILIAN		CIVILIAN				
d. Cannon, Jeremy	CIVILIAN	CIVILIAN		STILLING.				
е.								
17. IS A 502 ISG/JAC ETHICS REVIEW REQUIRED (JER DOD 5500.07-R)? YES NO								
I CERTIFY ANY HUMAN OR ANIMAL RESEARCH RELATED STUDIES WERE APPROVED AND PERFORMED IN STRICT ACCORDANCE WITH 32 CFR 219, AFMAN 40-401_IP, AND 59 MDWI 41-108. I HAVE READ THE FINAL VERSION OF THE ATTACHED MATERIAL AND CERTIFY THAT IT IS AN ACCURATE MANUSCRIPT FOR PUBLICATION AND/OR PRESENTATION.								
18. AUTHOR'S PRINTED NAME, RANK, GRAD John Hunninghake, 0-3, MC	19. AUTHOR'S SIG	GNATURE 268153108		20. DATE December 05, 2016				
21. APPROVING AUTHORITY'S PRINTED NA Edward McCann, 0-4, MC, Pulmonary Fe		PPROVING AUTHORITY'S SIGNATURE NEDWARD.T.1244108845 December 08,		23. DATE December 08, 2016				

PROCESSING OF PROFES	SIONAL MEDICAL	RESEAF	RCH/TECHNICAL PUBLICATIONS/PRESE	NTATIONS				
1st ENDORSEMENT (59 MDW/SGVU Use Only)								
TO: Clinical Research Division 59 MDW/CRD	24. DATE RECEIVED		25. ASSIGNED PROCESSING REQUEST FILE NUM	MBER				
Contact 292-7141 for email instructions.	December 12, 2016		17013					
26. DATE REVIEWED		2	27. DATE FORWARDED TO 502 ISG/JAC					
December 27, 2016								
28. AUTHOR CONTACTED FOR RECOMMENDED OR NECESSARY CHANGES: NO YES If yes, give date.								
29. COMMENTS APPROVED DISAPPROVED								
Case study presentation of prolonged ECLS transfer. Appropriate disclaimers included and no COI noted.								
Cuse study presentation of prototogen areas and prototogen areas and prototogen areas areas and prototogen areas a								
				8				
30. PRINTED NAME, RANK/GRADE, TITLE	OF REVIEWER	3	31. REVIEWER SIGNATURE	32. DATE				
Kevin Kupferer/GS13/Human Research	Kevin Kupferer/GS13/Human Research Subject Protection Expert			December 27, 2016				
2nd ENDORSEMENT (502 ISG/JAC Use On	ly)							
33. DATE RECEIVED			34. DATE FORWARDED TO 59 MDW/PA					
ARRENTS ARRENTS (In con	npliance with security and	policy revi	ew directives.) DISAPPROVED					
35. COMMENTS APPROVED (In con	ipilatice with security and	policy revi	EN directives.)					
ON THE NAME BANKINGBARE TITLE	OF DEVIEWED		37. REVIEWER SIGNATURE	38. DATE				
36. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER			37. REVIEWER SIGNATURE	00. <i>D</i> /112				
3rd ENDORSEMENT (59 MDW/PA Use Only)								
39. DATE RECEIVED			40. DATE FORWARDED TO 59 MDW/SGVU					
January 03, 2017 January 03, 2017			January 04, 2017					
41. COMMENTS APPROVED (In compliance with security and policy review directives.)								
0								
42. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER			43. REVIEWER SIGNATURE	44. DATE				
Kevin Iinuma, SSgt/E-5, 59 MDW Pub			INUMA.KEVIN.MITSUGU.1296227	January 04, 2017				
			Gase and it is an about an one and an one and					
4th ENDORSEMENT (59 MDW/SGVU Use Only) 45. DATE RECEIVED 46. SENIOR AUTHOR NOTIFIED BY PHONE OF APPROVAL OR DISAPPROVAL								
45. DATE RECEIVED	98	☐ YES		FT MESSAGE				
47. COMMENTS APPROVED DISAPPROVED								
				<u> </u>				
48. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER			49. REVIEWER SIGNATURE	50. DATE				

FIRST TRANSATLANTIC TRANSPORT ON EXTRACORPOREAL LIFE SUPPORT FOR HYPERCAPNEIC RESPIRATORY FAILURE

John Hunninghake, Andrew Skabelund, Scott Hagedorn, Jeremy Cannon

When conventional ventilation is unsuccessful, extra corporeal life support (ECLS) can be used to provide total lung support to patients who require adjunctive oxygenation (ECMO) or removal of excess carbon dioxide (ECCOR). Numerous reports have documented air transport of patients on ECLS, but flight times are usually <3 hours. We report the first documented case of a successful transatlantic transport of an adult patient on ECLS for hypercapneic respiratory failure in the initial stages of her prolonged clinical course to lung transplantation. The patient is a 31year-old non-smoking female with a yearlong history of worsening cough and exertional dyspnea who developed acute hypercapneic respiratory failure. After failed attempts on a conventional ventilator, she was placed on venovenous ECLS. Weaning attempts were unsuccessful due to a rapid rise in her PaCO2 upon removal of the circuit. On ECLS day 10, she was transported by a US Air Force Critical Care Air Transport Team from Germany to a military treatment facility in Texas. The entire transport process was nearly 24 hours and 8600 km. After failed attempts to wean from ECLS again due to PaCO2 retention, a lung transplantation evaluation was initiated on ECLS day 23. While on ECLS, she her physical and nutritional status significant improved with daily physical therapy. After 90 days on ECLS, the patient had gained 6 kg and could walk almost a mile on the treadmill. On ECLS day 94, the patient underwent an uncomplicated bilateral lung transplant. Pathology of the explanted lungs was consistent with a rare case of latestage diffuse panbronchiolitis. This case is unique for multiple reasons: the first successful transatlantic transport of an adult patient on ECLS over a remarkable distance and time duration; the successful use of ECLS for hypercapneic respiratory failure; and the use of an ECLS bridge for this patient to gain the physical and nutritional reserve required to tolerate her lung transplantation, which would not have been feasible if she had been on a conventional ventilator.

[&]quot;The views expressed are those of the author(s) and do not reflect the official views or policy of the Department of Defense or its Components."